MX2025010674A - Forma cristalina - Google Patents

Forma cristalina

Info

Publication number
MX2025010674A
MX2025010674A MX2025010674A MX2025010674A MX2025010674A MX 2025010674 A MX2025010674 A MX 2025010674A MX 2025010674 A MX2025010674 A MX 2025010674A MX 2025010674 A MX2025010674 A MX 2025010674A MX 2025010674 A MX2025010674 A MX 2025010674A
Authority
MX
Mexico
Prior art keywords
crystalline form
fluoro
ynyl
isoindoline
pyrrolo
Prior art date
Application number
MX2025010674A
Other languages
English (en)
Inventor
Philip Anthony Corner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2025010674A publication Critical patent/MX2025010674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente memoria descriptiva se relaciona con una forma cristalina de (3S)-2-[(5-amino-6 fluoro-1H-pirrolo[3,2-b]piridin-2-il)metil]-1'-but-2-inil-6-fluoro-espiro[isoindolina-3,3'-pirrolidina] 1,2'-diona, y con composiciones y usos de esta.
MX2025010674A 2023-03-13 2025-09-10 Forma cristalina MX2025010674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23161547 2023-03-13
PCT/EP2024/056495 WO2024188999A1 (en) 2023-03-13 2024-03-12 Crystalline form

Publications (1)

Publication Number Publication Date
MX2025010674A true MX2025010674A (es) 2025-10-01

Family

ID=85601718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025010674A MX2025010674A (es) 2023-03-13 2025-09-10 Forma cristalina

Country Status (9)

Country Link
EP (1) EP4680340A1 (es)
JP (1) JP2026508943A (es)
KR (1) KR20250155619A (es)
CN (1) CN120917029A (es)
AU (1) AU2024236796A1 (es)
CL (1) CL2025002744A1 (es)
IL (1) IL323224A (es)
MX (1) MX2025010674A (es)
WO (1) WO2024188999A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2026114356A1 (zh) * 2024-11-29 2026-06-04 普罗思特(南京)生物科技有限公司 含氮杂环化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
EP4402143A1 (en) 2021-09-13 2024-07-24 Astrazeneca AB Spirocyclic compounds

Also Published As

Publication number Publication date
IL323224A (en) 2025-11-01
CL2025002744A1 (es) 2026-01-02
KR20250155619A (ko) 2025-10-30
AU2024236796A1 (en) 2025-10-30
WO2024188999A1 (en) 2024-09-19
JP2026508943A (ja) 2026-03-13
EP4680340A1 (en) 2026-01-21
CN120917029A (zh) 2025-11-07

Similar Documents

Publication Publication Date Title
CA2424600A1 (en) Aliphatic nitrogenous five-membered ring compounds
AU5921394A (en) HIV protease inhibitors useful for the treatment of AIDS
GEP20063831B (en) Substituted bicyclic derivatives for treatment of abnormal cell growth
IL172833A0 (en) Pyrimidine-2,4-dione derivatives and pharmaceutical compositions containing the same
PT1467735E (pt) Polimorfos de hidrogenossulfato de clopidogrel
DE69915027D1 (de) Heteroaromatische bizyklische Verbindungen mit Antikrebswirkung
CA2195027A1 (en) HIV Protease Inhibitors Useful for the Treatment of AIDS
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
GEP20074210B (en) Tropane derivatives as ccr5 modulators
MY137969A (en) Crystal form of asenapine maleate
BR0310057A (pt) melhoria do desenvolvimento de catarata e outras doenças oftálmicas
WO2006121831A3 (en) Hiv integrase inhibitors
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP4617276A3 (en) Pyruvate kinase r (pkr) activating compositions
WO2007083188A3 (en) Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative
MX2025001384A (es) Forma cristalina de derivado triciclico fusionado y metodo de preparacion
CL2025002744A1 (es) Forma cristalina.
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
EP4545078A3 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
MXPA05008400A (es) Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos.
MX2009001141A (es) Derivados de acido tieno[3,2-c]piridin-2-carboxilico.
MXPA05007937A (es) Agentes antibacterianos.